IMPACT OF MICROVASCULAR DISEASE ON CARDIORENAL OUTCOMES IN TYPE 2 DIABETES: AN ANALYSIS FROM THE LEADER AND SUSTAIN-6 CLINICAL TRIALS

被引：0
|
作者：
Verma, Subodh [1 ]
Bain, Stephen C. [1 ]
Honore, Julie Broe [1 ]
Mann, Johannes F. E. [1 ]
Nauck, Michael A. [1 ]
Pratley, Richard E. [1 ]
Rasmussen, Soren [1 ]
Ripa, Maria Sejersten [1 ]
Zinman, Bernard [1 ]
Buse, John [1 ]
机构：
[1] Novo Nordisk AS, Soborg, Denmark
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2019年 / 73卷 / 09期
关键词：
D O I：
10.1016/S0735-1097(19)32293-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
911-04
引用
收藏
页码：1687 / 1687
页数：1
相关论文
共 50 条
  • [21] Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
    Lim, Lee-Ling
    Chow, Elaine
    Chan, Juliana C. N.
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2023, 19 (03) : 151 - 163
  • [22] Microvascular disease and cardiovascular outcomes among individuals with type 2 diabetes
    Kaze, Arnaud D.
    Santhanam, Prasanna
    Erqou, Sebhat
    Bertoni, Alain G.
    Ahima, Rexford S.
    Echouffo-Tcheugui, Justin B.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 176
  • [23] Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
    Lee-Ling Lim
    Elaine Chow
    Juliana C. N. Chan
    [J]. Nature Reviews Endocrinology, 2023, 19 : 151 - 163
  • [24] Blood pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
    Ruilope, Luis M.
    Agarwal, Rajiv
    Anker, Stefan D.
    Filippatos, Gerasimos
    Pitt, Bertram
    Rossing, Peter
    Sarafidis, Pantelis
    Schmieder, Roland E.
    Joseph, Amer
    Rethemeier, Nicole
    Nowack, Christina
    Bakris, George L.
    [J]. HYPERTENSION, 2022, 79 (12) : 2685 - 2695
  • [25] EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS
    Tuttle, Katherine
    Cherney, David
    Hadjadj, Samy
    Idorn, Thomas
    Mosenzon, Ofri
    Perkovic, Vlado
    Rasmussen, Soren
    Wolthers, Benjamin
    Bain, Stephen C.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 152 - 152
  • [26] Management of Risk Factors in Patients with Type-2 Diabetes New Results from the LEADER- and SUSTAIN 6 Study
    Schamarek, Imke
    [J]. DIABETOLOGE, 2022, 18 (03): : 327 - 328
  • [27] Management von Risikofaktoren bei Typ-2-DiabetesNeue Ergebnisse der LEADER- und SUSTAIN 6 StudieManagement of risk factors in type 2 diabetes patientsNew results from the LEADER and SUSTAIN 6 studies
    Imke Schamarek
    [J]. Der Diabetologe, 2022, 18 (3): : 327 - 328
  • [28] GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials
    Giugliano, Dario
    Maiorino, Maria Ida
    Bellastella, Giuseppe
    Longo, Miriam
    Chiodini, Paolo
    Esposito, Katherine
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (11): : 2576 - 2580
  • [29] Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials
    Yin, Dao-Gen
    Ding, Liang-Liang
    Zhou, Hai-Rong
    Qiu, Mei
    Duan, Xue-Yan
    [J]. ENDOCRINE JOURNAL, 2021, 68 (06) : 739 - 742
  • [30] Cardiovascular Outcome Trials in Diabetes: Will the EMPA-REG OUTCOME and LEADER Trials Influence Clinical Decisions in Type 2 Diabetes?
    Bajaj, Harpreet Singh
    Zinman, Bernard
    [J]. CANADIAN JOURNAL OF DIABETES, 2016, 40 (05) : 379 - 381
12345